If approved, vorasidenib would be the first targeted therapy in IDH-mutant diffuse glioma, a malignant and incurable brain tumor

如果获得批准，vorasidenib将成为IDH突变型弥漫性胶质瘤（一种恶性且无法治愈的脑肿瘤）的第一种靶向治疗

In clinical studies, vorasidenib has demonstrated strong blood-brain barrier penetrance alongside clinically meaningful and statistically significant improvements in progression-free survival and time-to-next intervention

在临床研究中，vorasidenib表现出强大的血脑屏障渗透性，同时在无进展生存期和下一次干预时间方面具有临床意义和统计学意义的改善

Approval of vorasidenib would mark Servier's sixth approval for a first-in-class treatment option in IDH-mutant cancers

沃拉西德尼的批准将标志着施维雅第六次批准IDH突变癌症的一流治疗方案

BOSTON and SURESNES, France, Feb. 20, 2024 /PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting accelerated assessment for the vorasidenib Marketing Authorization Application (MAA).

波士顿和SURESNES，法国，2024年2月20日/PRNewswire/--全球肿瘤学领导者Servier专注于为其服务的患者提供有意义的治疗进展，今天宣布FDA对沃拉西德尼新药申请（NDA）的申请受理和优先审查，以及欧洲药品管理局授予vorasidenib营销授权应用程序（MAA）加速评估。

This innovative targeted therapy is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma. If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth approval across IDH-mutant cancers.

这种创新的靶向治疗是一种口服，选择性，高脑渗透性的突变型异柠檬酸脱氢酶1和2（IDH1/2）酶双重抑制剂，用于治疗IDH突变型弥漫性胶质瘤。如果获得批准，vorasidenib将成为IDH突变型神经胶质瘤患者的一流靶向治疗，并将标志着Servier对IDH突变型癌症的第六次批准。

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 20, 2024, and the the European Commission approval is anticipated in the second half of 2024..

FDA已指定2024年8月20日为《处方药用户费用法》（PDUFA）行动日期，预计欧盟委员会将于2024年下半年批准。。

'In the realm of glioma treatment, innovation has been stagnant for nearly a quarter-century, posing challenges for patients who, post-surgery, may opt to defer treatment due to concerns around potential toxic side effects. As a drug specifically designed to be highly blood-brain barrier penetrant, vorasidenib has demonstrated clinically meaningful efficacy in patients with IDH1/2 mutant gliomas alongside a consistently manageable safety profile,' said Susan Pandya, M.D., Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology, Servier.

“在神经胶质瘤治疗领域，近四分之一世纪以来，创新一直停滞不前，这给手术后可能因担心潜在的毒副作用而选择推迟治疗的患者带来了挑战。Servier癌症代谢全球发展肿瘤学和免疫肿瘤学负责人医学博士苏珊·潘迪亚（SusanPandya）说，作为一种专门设计为具有高度血脑屏障渗透性的药物，沃拉西德尼在IDH1/2突变型神经胶质瘤患者中显示出具有临床意义的疗效，同时具有持续可控的安全性。

'This promising outcome brings hope to patients grappling with IDH-mutant diffuse gliomas, offering a potential breakthrough for those eagerly awaiting a new therapeutic option.'.

“这一有希望的结果为患有IDH突变型弥漫性神经胶质瘤的患者带来了希望，为那些迫切等待新治疗选择的患者提供了潜在的突破。”。

Adult-type diffuse gliomas represent approximately 81% of primary malignant brain tumors. Of those, approximately 20% harbor an IDH mutation, including 100% of grade 2 and grade 3 adult-type diffuse gliomas, as well as a much smaller portion of the grade 4 tumors.1,2 Testing for IDH mutations is essential for the accurate diagnosis of adult-type diffuse gliomas and can offer more information on the pathogenesis and prognosis of the disease.3 The 2021 WHO Classification includes disease defining histologic and molecular features, including IDH mutation status, to diagnose adult-type diffuse gliomas.4 Additionally, the National Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend IDH mutation testing in all patients with glioma, noting IDH mutation status impacts diagnosis, prognosis and treatment recommendations.5 .

成人型弥漫性神经胶质瘤约占原发性恶性脑肿瘤的81%。其中，大约20%具有IDH突变，包括100%的2级和3级成人型弥漫性神经胶质瘤，1,2 IDH突变检测对于准确诊断成人型弥漫性神经胶质瘤至关重要，可以提供更多关于该疾病发病机制和预后的信息。3 2021年WHO分类包括疾病定义的组织学和分子特征，包括IDH突变状态，此外，国家肿瘤学临床实践指南（NCCN指南）建议对所有胶质瘤患者进行IDH突变检测，注意IDH突变状态影响诊断，预后和治疗建议。

'As the pioneer in the field of mutant IDH inhibition, Servier has consistently spearheaded the development of cutting-edge treatment options for various cancer types characterized by IDH mutations. The compelling efficacy results observed with vorasidenib in the INDIGO study underscore its full potential to emerge as the benchmark treatment for patients grappling with IDH-mutant diffuse glioma harboring IDH1/2 mutations,' stated Claude Bertrand, Executive Vice-President of Research & Development and Chief Scientific Officer at Servier.

作为突变IDH抑制领域的先驱，Servier一直带头开发以IDH突变为特征的各种癌症类型的尖端治疗选择。施维雅研究与开发执行副总裁兼首席科学官克劳德·伯特兰（ClaudeBertrand）表示，在INDIGO研究中观察到的伏拉西替尼令人信服的疗效结果强调了其作为患有IDH1/2突变的IDH突变弥漫性神经胶质瘤患者的基准治疗的全部潜力。

'The submission of global regulatory filings for vorasidenib serve as validation of Servier's global oncology commitment while marking a possibly significant milestone for patients who have endured more than two decades without access to new therapeutic solutions.' .

“提交沃拉西德尼的全球监管文件是对施维雅全球肿瘤学承诺的验证，同时对于那些忍受了20多年而无法获得新治疗方案的患者来说，这可能是一个重要的里程碑。”。

The submissions are based on results from the pivotal Phase 3 INDIGO clinical trial, which met its primary endpoint of progression-free survival (PFS) per blinded independent review committee (BIRC) and key secondary endpoint of time to next intervention (TTNI) at the prespecified second interim analysis.

提交的材料是基于关键的3期INDIGO临床试验的结果，该试验符合每个盲法独立审查委员会（BIRC）的无进展生存期（PFS）的主要终点和下一次干预时间（TTNI）的关键次要终点。预先指定的第二次中期分析。

The primary endpoint, PFS per BIRC, was statistically significant and clinically meaningful in favor of the vorasidenib arm (Hazard Ratio [HR], 0.39; 95% Confidence Interval [CI], 0.27 to 0.56; 1-sided P=0.000000067), median PFS for vorasidenib and placebo was 27.7 and 11.1 months, respectively. TTNI was also statistically significant (HR, 0.26; 95% CI, 0.15 to 0.43; 1-sided P=0.000000019).

主要终点，每个BIRC的PFS，对vorasidenib组有统计学意义和临床意义（风险比[HR]，0.39；95%置信区间[CI]，0.27-0.56；单侧P=0.000000067），vorasidenib和安慰剂的中位PFS分别为27.7和11.1个月。TTNI也具有统计学意义（HR，0.26；95%CI，0.15至0.43；单侧P=0.0000000 19）。

Median TTNI was not reached for vorasidenib and was 17.8 months for placebo. Vorasidenib was also shown to reduce the tumor volume by a mean of 2.5% (TGR of –2.5%; 95% CI: -4.7% to -0.2%) every 6 months, while tumor volume increased by a mean of 13.9% (TGR of 13.9%; 95% CI: 11.1% to 16.8%) every 6 months for patients randomized to the placebo arm, as measured by a blinded independent radiology committee..

vorasidenib未达到TTNI中位数，安慰剂为17.8个月。Vorasidenib还显示每6个月平均减少肿瘤体积2.5%（TGR为-2.5%；95%CI为-4.7%至-0.2%），而肿瘤体积平均增加13.9%（TGR为13.9%；95%CI为11.1%至16.8%），每6个月随机分配到安慰剂组的患者，由盲法独立放射学委员会测量。。

The INDIGO study showed that vorasidenib was well-tolerated, and its safety profile was consistent with results from the Phase 1 studies.

INDIGO研究表明，vorasidenib耐受性良好，其安全性与第一阶段研究的结果一致。

The results of INDIGO were presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in The New England Journal of Medicine. The results of additional secondary endpoints, including vorasidenib's impact on tumor growth rate (TGR) of IDH-mutant gliomas, were presented at the 2023 Annual Meeting of the Society for Neuro-Oncology (SNO) among other presentations including results on health-related quality of life, seizure control, neurocognition, and preliminary molecular translational analyses..

靛蓝的研究结果发表在2023年美国临床肿瘤学会（ASCO）年会上，同时发表在《新英格兰医学杂志》上。其他次要终点的结果，包括vorasidenib对IDH突变型神经胶质瘤肿瘤生长率（TGR）的影响，在2023年神经肿瘤学会（SNO）年会上发表，其中包括与健康相关的生活质量，癫痫发作控制，神经认知和初步分子翻译分析的结果。。

Priority Review is granted to FDA applications for medicines that, if approved, would provide significant improvements in the effectiveness or safety of the treatment, diagnosis or prevention of serious conditions.6 Vorasidenib was granted Fast Track Designation by the FDA in February 2023 and Breakthrough Therapy Designation by the FDA in August 2023..

优先审查FDA的药物申请，如果获得批准，将大大提高治疗、诊断或预防严重疾病的有效性或安全性。6沃拉西德尼于2023年2月被FDA授予快速通道指定，并于2023年8月被FDA授予突破性治疗指定。。

The EMA's accelerated assessment is granted if the Committee for Medicinal Products for Human Use (CHMP) decides the new medicine is expected to be of major public health interest, particularly from the viewpoint of therapeutic innovation.7

如果人类使用药品委员会（CHMP）决定新药预计将具有重大的公共卫生利益，特别是从治疗创新的角度来看，EMA的加速评估将获得批准

Servier has also submitted an application for project Orbis member countries, including Brazil, Canada, Australia, Israel and Switzerland. In addition, Servier plans to submit a Marketing Application in the United Kingdom if a positive CHMP opinion is received. More information about Project Orbis can be found on the FDA website..

施维雅还提交了Orbis项目成员国的申请，其中包括巴西、加拿大、澳大利亚、以色列和瑞士。此外，如果收到CHMP的积极意见，施维雅计划在英国提交营销申请。有关Orbis项目的更多信息，请访问FDA网站。。

In its ongoing commitment to addressing patient's needs, Servier recognizes that patients and their physicians may believe that a patient with a serious or immediately life-threatening disease could benefit from Servier's investigational drugs. An Expanded Access Program, also known as 'compassionate use,' is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials.

在不断致力于满足患者需求的过程中，施维雅认识到患者及其医生可能认为患有严重或立即危及生命的疾病的患者可以从施维雅的研究药物中受益。扩大获取计划，也称为“同情使用”，是一种潜在的途径，可以让患有立即危及生命的疾病或严重疾病或病症的患者获得研究性医疗产品，以便在临床试验之外进行治疗。

More information about Servier's expanded access program can be found at clinicaltrials.gov..

有关施维雅扩展访问计划的更多信息，请访问clinicaltrials.gov。。

About the INDIGO Phase 3 Trial (NCT04164901)

关于INDIGO 3期试验（NCT04164901）

INDIGO was a registration-enabling Phase 3 global, randomized, double-blind placebo-controlled study of vorasidenib in patients with residual or recurrent grade 2 glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation who have undergone surgery as their only treatment. Results were published in The New England Journal of Medicine..

INDIGO是一项注册的3期全球，随机，双盲安慰剂对照研究，用于vorasidenib治疗残留或复发的2级胶质瘤患者，异柠檬酸脱氢酶1/2（IDH1/2）突变，他们接受了手术作为唯一的治疗方法。研究结果发表在《新英格兰医学杂志》上。。

About Glioma8

关于胶质瘤8

Adult-type diffuse gliomas represent approximately 81% of primary malignant brain tumors. Of those, approximately 20% harbor an IDH mutation, including 100% of grade 2 and grade 3 adult-type diffuse gliomas, as well as a much smaller portion of the grade 4 tumors.1,2 Establishing the IDH mutation status of these tumors is essential to both diagnosis and prognosis, per the 2021 WHO classification of CNS tumors and the NCCN treatment guidelines, respectively. As of 2021, adult-type diffuse gliomas are sub-divided into only three categories:.

成人型弥漫性神经胶质瘤约占原发性恶性脑肿瘤的81%。其中，大约20%患有IDH突变，包括100%的2级和3级成人型弥漫性神经胶质瘤，以及4级肿瘤中的一小部分[1,2]。根据2021年WHO中枢神经系统肿瘤分类和NCCN治疗指南，确定这些肿瘤的IDH突变状态对于诊断和预后都至关重要。截至2021年，成人型弥漫性神经胶质瘤仅分为三类：。

Astrocytoma, IDH-mutant (CNS WHO grades 2-4)

星形细胞瘤，IDH突变（CNS WHO 2-4级）

Oligodendroglioma, IDH-mutant and 1p19q-codeleted (CNS WHO grades 2-3)

少突胶质细胞瘤，IDH突变和1p19q编码（CNS WHO 2-3级）

Glioblastoma, IDH-wildtype (CNS WHO grade 4)

胶质母细胞瘤，IDH野生型（CNS WHO 4级）

About Servier in Oncology

关于施维雅肿瘤学

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets..

施维雅是肿瘤学领域的全球领导者，专注于为其服务的患者提供有意义的治疗进展。施维雅由一家非营利性基金会管理，以长远的眼光进行创新，不受投资者的影响，也不受外界追逐短期货币目标的压力。。

As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-treat cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves.

作为肿瘤学领域的领导者，施维雅大大加快了对难治性癌症的投资，其超过50%的研究和开发致力于在整个肿瘤学中未满足需求的领域取得重大进展，并有可能改变其服务的患者的生活。

Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition..

在这些领域，施维雅是突变IDH抑制的领导者，拥有美国和欧盟批准的第一种突变IDH1抑制剂，该公司继续推动靶向突变IDH抑制背后的科学。。

Servier's commitment to therapeutic progress guides its collaboration strategy. While many companies across the industry are scaling back investments, Servier is actively building alliances, completing acquisitions, conducting licensing deals and entering new partnerships that can help to accelerate access to therapies for patients in need.

施维雅对治疗进展的承诺指导了其合作策略。虽然业内许多公司都在缩减投资，但施维雅正在积极建立联盟，完成收购，开展许可协议，并建立新的合作伙伴关系，以帮助有需要的患者加速获得治疗。

With the company's commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier is dedicated to bringing the promise of tomorrow to the patients it serves..

凭借公司的商业专业知识、全球影响力、科学专业知识以及对卓越临床的承诺，施维雅致力于为其服务的患者带来明天的承诺。。

Press Contacts

新闻联系人

Servier Group (Global)[email protected]

施维雅集团（全球）[受电子邮件保护]

Servier Pharmaceuticals (U.S.)Nathan Mellor[email protected]

施维雅制药（美国）Nathan Mellor[受电子邮件保护]

Disclosures

披露

This release contains general information about the Servier Group and its entities (hereinafter 'Servier and its Affiliates') and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect..

本版本包含施维雅集团及其实体（以下简称“施维雅及其附属公司”）的一般信息，仅供参考。信息被认为是可靠的；但是，施维雅及其关联公司不对本协议或其他方式提供的信息的准确性或完整性做出任何陈述，如果发现信息在任何方面不准确或不完整，则不承担合同、侵权、疏忽或其他方面的责任或责任。。

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks..

施维雅及其关联公司不担任本信息接收者的顾问，继续进行任何交易的最终决定仅取决于本信息接收者。因此，在进行任何拟议交易之前，该信息的接收者应在不依赖施维雅或其关联公司的情况下，确定交易的经济风险和优点，以及法律、税务和会计特征和后果，并且能够承担这些风险。。

This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA.

本声明还包含前瞻性声明，这些声明受到不同程度的不确定性和风险的影响。研究性新药和适应症需要进一步的科学和医学审查以及监管部门的批准。它们未经FDA批准使用。

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

对本文件的任何依赖均完全由依赖者承担风险。本文件中包含的信息既不是出售要约，也不是交易要约的邀约。

The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest.

本文件的内容仅为摘要，不完整，不包括施维雅及其附属公司的所有重要信息，包括潜在的利益冲突。

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete..

在适用法律法规允许的最大范围内，施维雅及其关联公司不承担与本文件有关的所有明示、暗示、法定或其他形式的陈述、保证、条件和保证，也不接受任何人的任何义务。在不影响上述一般性的情况下，施维雅及其关联公司不保证或声明本文件中包含的信息或意见是准确或完整的。。

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same.

在适用法律法规允许的最大范围内，施维雅及其关联公司不承担任何损失、损害或费用，无论是直接的还是间接的，无论是由于合同、侵权（包括疏忽）、严格责任还是其他原因引起的，无论是直接的、间接的、偶然的、后果性的，由本文件引起或与之相关的惩罚性或特殊损害赔偿，包括（但不限于）根据本文件采取的任何行动。

The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice..

本文件中表达的估计、策略和观点基于过去或当前的数据和信息，如有更改，恕不另行通知。。

1  Louis, D. et. al (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary, Neuro-Oncology, 23(8): 1231–1251. https://doi.org/10.1093/neuonc/noab106. Accessed February 2024. 2 Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J.

1 Louis，D.等人（2021年）。2021年世界卫生组织中枢神经系统肿瘤分类：摘要，神经肿瘤学，23（8）：1231-1251https://doi.org/10.1093/neuonc/noab106.2024年2月访问。2奥斯特罗姆（Ostrom，Q.T.），普莱斯（Price，M.），内夫（Neff），C。乔菲（Cioffi），G。韦特（Waite），K。A。克鲁奇科（Kruchko），C。和巴恩霍尔茨-斯隆（Barnholtz-Sloan），J。

S. (2022). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro-oncology, 24(Suppl 5), v1–v95. https://doi.org/10.1093/neuonc/noac202. Accessed February 2024.3 Isocitrate Dehydrogenase. Science Direct. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/isocitrate-dehydrogenase.

S、 （2022年）。CBTRUS统计报告：2015-2019年在美国诊断出的原发性脑和其他中枢神经系统肿瘤。神经肿瘤学，24（补充5），v1-v95。https://doi.org/10.1093/neuonc/noac202.2024年2月访问。3异柠檬酸脱氢酶。科学指导。https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/isocitrate-dehydrogenase.

Accessed February 2024.4 Antonelli M, Poliani PL. Adult type diffuse gliomas in the new 2021 WHO Classification. Pathologica. 2022 Dec;114(6):397-409. doi: 10.32074/1591-951X-823. PMID: 36534419; PMCID: PMC9763975.5 NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Brain Cancer Gliomas 2021.

2024年2月访问。Antonelli M，Poliani PL。2021年WHO新分类中的成人型弥漫性神经胶质瘤。病理学。2022年12月；114（6）：397-409。内政部：10.32074/1591-951X-823。PMID:36534419；PMCID:PMC9763975.5 NCCN。2021年脑癌神经胶质瘤肿瘤学临床实践指南（NCCN Guidelines®）。

© National Comprehensive Cancer Network, Inc. 2023. Accessed February 2024. https://www.nccn.org/patients/guidelines/content/PDF/brain-gliomas-patient.pdf 6 U.S. Food and Drug Administration (FDA). Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

©National Comprehensive Cancer Network，Inc.2023年。2024年2月访问。https://www.nccn.org/patients/guidelines/content/PDF/brain-gliomas-patient.pdf6美国食品和药物管理局（FDA）。快速通道，突破性治疗，加速批准，优先审查。https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

Accessed February 2024.7 European Medicines Agency (EMA). Accelerated assessment. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/accelerated-assessment. Accessed February 2024.8 Neuro Oncology. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. https://academic.oup.com/neuro-oncology/article/23/8/1231/6311214.

2024年2月访问。7欧洲药品管理局（EMA）。加速评估。https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/accelerated-assessment.2024年2月访问。8神经肿瘤学。2021年世卫组织中枢神经系统肿瘤分类：摘要。（笑声）https://academic.oup.com/neuro-oncology/article/23/8/1231/6311214.

Accessed February 2024..

2024年2月访问。。

SOURCE Servier Pharmaceuticals

来源：施维雅制药